A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059

导出原文传递

翻译打印收藏纠错

作者： Ignacio, Rachel A. Bender ^[1] ; Lee, Jeannette Y. ^[2] ; Rudek, Michelle A. ^[3] ; Dittmer, Dirk P. ^[4] ; Ambinder, Richard F. ^[5] ; Krown, Susan E.

作者单位： Mem Sloan Kettering Canc Ctr, Dept Med, Div Med Oncol, 1275 York Ave, New York, NY 10021 USA ^[1] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA USA ^[2] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC USA ^[3] Univ Arkansas Med Sci, Dept Biostat, Little Rock, AR 72205 USA ^[4] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA ^[5]

关键词 Kaposi's sarcoma (KS)vascular endothelial growth factor (VEGF)vascular endothelial growth factor inhibitor (VEGF inhibitor)Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)HIV/AIDS-related malignancy pharmacokinetics (PK)

发布时间 2017-04-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交